Orladeyo (berotralstat)

Search documents
BioCryst to buy Astria Therapeutics for $700m in enterprise value
Yahoo Finance· 2025-10-15 09:16
BioCryst Pharmaceuticals has signed a definitive agreement to buy Astria Therapeutics with a mix of cash and stock transactions. The deal values Astria at an implied $13 per share, culminating in an enterprise value of around $700m. The companies’ boards of directors have unanimously approved the acquisition and the transaction will be finalised in the first quarter of 2026. Upon completion, Astria CEO Jill Milne will join the BioCryst board of directors. The acquisition is expected to provide strategic ...